A b s t r a c t
Lobular neoplasia (LN) both in the form of atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) is regarded as a definitive risk indicator for the development of invasive ductal or lobular carcinoma in both breasts. This association was first reported by Foote and Stewart 1 in 1941, by demonstrating the coexistence of LCIS and invasive lobular carcinoma in 60% of their cases. Compared with the general population, the risk of breast cancer development is elevated up to 5-fold after a diagnosis of ALH and up to 10-fold after a diagnosis of LCIS. [2] [3] [4] [5] [6] The term lobular neoplasia was introduced by Haagensen et al 7 to discriminate it from ductal neoplasia, and they recommended a conservative approach in dealing with these lesions.
Currently, there are no well-established guidelines for the treatment of patients who receive a diagnosis of LN based on core-needle biopsy (CNB). Instead, the significance of these lesions on core biopsy is controversial, with relatively small samples described in existing literature. The most common treatment options are careful observation along with mammographic and clinical follow-up, and more recently, endocrine chemoprophylaxis for high-risk patients. The usefulness of surgical follow-up excision (FUE) is still debatable. [8] [9] [10] [11] [12] [13] [14] Lobular neoplasia is typically asymptomatic and often lacks discriminating mammographic findings. 15 Several imaging studies have found an association between microcalcifications and LN in significant numbers of cases. [16] [17] [18] In addition to microcalcifications, LN may display radiographic findings of masses or architectural distortion. 19, 20 The goals of our study are to review a relatively large number of cases diagnosed as pure LN, without invasive Upon completion of this activity you will be able to:
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carcinoma (IC), ductal carcinoma in situ (DCIS), or atypical ductal hyperplasia (ADH) on CNB that were followed by subsequent surgical excision, and correlate these cases with radiologic findings and surgical excision diagnoses. This is to further develop management guidelines for LN diagnosed on CNB.
Materials and Methods
This study was approved by the University of Pittsburgh School of Medicine institutional review board. A pathology database search at Magee-Women's Hospital of the University of Pittsburgh Medical Center (UPMC) was performed for a study period of 66 months (January 2006 to July 2011). The biopsy specimens were received in separate formalin containers labeled "with calcification" and "without calcification" in most cases. Tissue cores were embedded in paraffin, sectioned, and leveled, and 5 slides were stained with H&E. Surgical excision specimens were fixed in 10% formalin, submitted entirely, and stained with H&E.
ALH was defined by uniform small cells filling and distending fewer than 50% of the terminal duct units of a lobule. The cells were discohesive and evenly spaced, with round nuclei and minimal pleomorphism. LCIS was diagnosed when the entire lobule was involved and more than 50% of the acini in the terminal duct units were distended. 21 In this article, we use the term lobular neoplasia to include ALH and LCIS. Pathologic findings were divided into 2 groups: group 1 (pure ALH) and group 2 (pure LCIS with or without ALH).
A total of 807 cases of LN were identified out of 20,260 breast core biopsies (4%). Of these, 243 (30.1%) cases were excluded because of history or synchronous IC or DCIS, 96 (11.9%) because of radiologic diagnosis of mass or lesion other than calcifications, 123 (15.2%) because of the presence of ADH or flat epithelial atypia (FEA), and 7 (0.9%) because of the presence of pleomorphic component of LCIS. Those cases were excluded because the surgeon intended to excise the lesions. Among the remaining 338 cases of classic type LN, 237 (70.1%) had FUE. All cases had a screening mammogram with calcifications. The breast core biopsies were stereotactic, ultrasound, or magnetic resonance imaging-guided in 233 (98.3%), 3 (1.3%), and 1 (0.4%), respectively ❚Table 1❚.
Patients' clinical information, history, biopsy, and excisional results were extracted from the pathology reports. The slides of both CNB and FUE for the cases upstaged to DCIS or IC were reviewed by 2 authors (C.Z. and M.M.D.).
At our institution, stereotactic and magnetic resonance imaging-guided biopsies are usually performed with 9-gauge vacuum-assisted needles with a 12-mm-long trough; ultrasound-guided biopsies are usually performed with 14-gauge non-vacuum-assisted needles. The radiographic Breast Imaging Reporting and Data System (BI-RADS) 22 scores (from 1-6) were recorded from the imaging data files. Cases were considered to be upstaged if FUE showed IC or DCIS.
Statistical Analysis
Data were entered and analyzed using SPSS 16 (SPSS for Windows, SPSS, Chicago, IL); for qualitative data, frequency and percentages were used, and for quantitative data, range, median, mean, and standard deviation were used. χ 2 , Fisher exact, and independent t test were used to test significance between groups, and the cutoff point to detect significance (P value) was less than or equal to .05. Table 1 illustrates the clinicopathologic and radiologic characteristics of LN cases with FUE biopsy that were included in the study. The mean and median ages of patients were 54 and 52 years, respectively (range, 28-79 years). The radiologic abnormalities reported for all cases and confirmed on biopsy showed calcium present mainly in fibrocystic changes, columnar cell changes, and benign breast ducts and stroma in most cases.
Results
Upstaging of cases was not statistically significant between the 2 groups, with a higher frequency seen in the LCIS than in the ALH group (P = .102). No cases from the pure ALH cases were upstaged to ILC. Two cases of LCIS were upstaged to invasive lobular carcinoma (ILC) (2.7%). One (0.6%) of 163 ALH cases and 1 (1.4%) of 74 LCIS cases were upstaged to invasive ductal carcinoma, and 4 (2.5%) of 163 ALH cases and 3 (4.1%) of 74 LCIS cases were upstaged to DCIS. Collectively, 5 (3.1%) of 163 pure ALH cases and 6 (8.1%) of 74 pure LCIS cases were upstaged to DCIS with or without IC ❚Table 2❚. The DCIS phenotypes were cribriform (5 cases) ❚Image 1E❚ and ❚Image 1F❚ or solid (2 cases), and nuclear grades were grade 1 (4 cases), grade 2 (2 cases), and grade 3 (1 case). Comedonecrosis was focally present in the 2 cases (Table 3) .
In cases upstaged to IC or DCIS specifically, specimens were obtained by 9-gauge Suros vacuum-assisted device (Suros Surgical Systems, Indianapolis, IN) (7 cases), 11-gauge vacuum-assisted core biopsy device (2 cases), 9-gauge Kopans needle (1 case) or 14-gauge biopsy device (1 case). The calcifications detected on mammography varied in description between clusters of pleomorphic to fine calcifications, some of which appear linear and uniform in shape with appearance of benign milk-of-calcium, and all calcifications were indeterminate (Table 3) .
Interestingly, high-risk lesions, eg, ADH with or without FEA and FEA in the absence of ADH were identified in FUE in 33 (20.2%) of 163 cases of pure ALH and 21 (28.4%) of 74 cases of pure LCIS with core biopsy diagnoses ❚Table 4❚.
No statistically significant difference was found in the BI-RADS score reported on core biopsy with upstaging of cases on FUE (P = .9). This may be because most cases were rendered a BI-RADS score of 4. The BI-RADS score was 4 in 230 (99.1%) of 232 cases, with no significant difference between the 2 groups or in relation to upstaging. The interval between the core biopsy and FUE ranges from 0.2 to 7 months (mean ± SD, 1.5 ± 1.1) ( 
Discussion
ALH and LCIS are often multifocal and not uncommonly present in the contralateral breast. They have generally been considered to be risk factors for the development of bilateral breast carcinoma, with relative risk rates for ALH being 4 to 5 times and for LCIS up to 8 to 10 times those reported in the literature. 18 This is in contrast to ADH and DCIS, which are considered by most as direct precursors to the development of malignancies. 23 Management of isolated lobular neoplasia found on core biopsy is a controversial topic. Many studies have examined the need for excision biopsy for LN diagnosed on breast core biopsy. The data in the literature reflect mixed recommendations, divided between reexcision 6,12,16-18,24 or not. 8, 23, 25, 26 Cancer at surgical excision ranged from 0 to 60%, which reflects the differences in the cases selected in addition to other factors. Pacelli et al 27 31 Shin and Rosen 32 reported no upstaging in (0/5) cases of ALH on core biopsy. Similarly, Zhang et al 33 and Liberman et al 34 reported no upstaging of ALH cases (0/8 and 0/4, respectively). The highest rates of upstaging of LCIS to carcinoma were reported to be 60%, 35 40% to 45%, 36 30% to 37%, 18, 33, 37 20% to 25%, 32, 34, 38, 39 and a meta-analysis showing 32% (77/241). 40 Upstaging of ALH was reported to be as high as 43%, 41 20% to 25%, 18, 37, 39, 42 14%, 30, 43 and 12.5%, 35 with a meta-analysis showing 19% (53/280). 40 The highest rates of upstaging of unspecified LN to carcinoma were reported to be 61%, 44, 45 35% to 46%, 16, 24, 46, 47 20% to 33%, 20, 48 15% to 14%, 35, [49] [50] [51] and 7%, 31 with a meta-analysis showing 29% (72/246). 40 The discrepancies in upstaging of LN in these studies may be because of selection criteria, such as the inclusion of patients with a previous history of breast carcinoma, and the presence of high-risk lesions such as ADH, pleomorphic LN, atypical papilloma, and radial scar. In addition, the inclusion of cases with radiographic findings other than calcifications may lead to an increased rate of upstaging. The patients included in our study had no other risk factor on clinicopathologic 
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❚Image 1❚ Representative cases diagnosed as lobular carcinoma in situ (A and C) or atypical lobular hyperplasia (E) on breast core biopsy with upstaging to infiltrating lobular carcinoma (B), tubular carcinoma (D) or cribriform ductal carcinoma in situ (F). Notice negative to weak positive membranous immunohistochemical stain for the dual E-cadherin/P120 with cytoplasmic expression of P120 (inset in A), negative to weak positive membranous immunohistochemical stain for E-cadherin (inset in C and E), and negative P63 myoepithelial marker around tubular carcinoma (inset in D). Arrows point to determinate calcifications associated with lobular carcinoma in situ.
examination (eg, history of invasive or DCIS, ADH, FEA, or pleomorphic LN) and radiologic abnormalities (eg, mass or architectural distortion), which may potentially by itself upstage the diagnosis. Additional drawbacks of these studies are the small number of cases studied and the lack of complete FUE in every case. Another drawback in the studies, including the current study, is that all studies are retrospective, which may suffer from selection bias by including those patients who underwent excision. However, 237 (70.1%) of 338 of our study patients had FUE, which minimizes selection bias. Another flaw in most of the studies, including the current study, is the lack of identification of the nature of the calcifications found on core biopsy. In most cases, it is likely that the calcifications on core biopsy were not "determinate" for LN-rather they were more likely to be associated with benign tissue elements.
To our knowledge, this is the largest retrospective study of the outcomes of follow-up surgical excision of LN found on breast core biopsy. The risk for DCIS and IC on FUE was 4.6%. The overall risk may be considered to be low to moderate and stratification of patients for excision should be considered on an individual basis. Age, for example, is a risk factor in upstaging with a higher rate of upstaging seen in women older than 50 years. Although the current study ❚Figure 1❚ Upstaging of lobular neoplasia on breast core biopsy to ductal carcinoma in situ or invasive carcinoma on follow-up excision biopsy according to clinicopathologic and epidemiologic data. ALH, atypical lobular hyperplasia; LCIS, lobular carcinoma in situ.
